RIGL earnings: real EPS beat/miss history, analyst consensus Buy, P/E 1.88. Updated 2026-07-23.
Rigel Pharmaceuticals (RIGL) Research Hub
Rigel Pharmaceuticals (RIGL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 47.24 USD (+0.04%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 1.88, market cap 0.71B. This hub links to the full technical, earnings and options research available for RIGL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 47.24 USD (+0.04%) |
| 52-week range | 32.71 USD – 49.9 USD |
| Trend regime | Range |
| 14-day RSI | 73.4 (Overbought) |
| Trailing P/E | 1.88 |
| Market cap | 0.71B |
| Dividend yield | 0.00% |
Available research for RIGL
Covered Call on RIGL: how it works, illustrative setup around the real 47.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RIGL: how it works, illustrative setup around the real 47.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RIGL: how it works, illustrative setup around the real 47.24 USD price, max profit/loss, breakeven and when to use it. Educational.
RIGL technical analysis: range, last 47.24 USD, RSI 73.4, 52w range 32.71 USD–49.9 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RIGL in?
Rigel Pharmaceuticals (RIGL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RIGL in an uptrend or downtrend?
As of 2026-09-11, RIGL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RIGL's trailing P/E ratio?
RIGL's trailing P/E is 1.88, with a market cap of 0.71B. See the earnings research page for full valuation detail.